FAS Antibody - #AF5342

(19)   (17)  
Product: FAS Antibody
Catalog: AF5342
Description: Rabbit polyclonal antibody to FAS
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Mol.Wt.: 37kD,50~70kD(Glycosylated); 38kD(Calculated).
Uniprot: P25445
RRID: AB_2837827

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Clonality:
Polyclonal
Specificity:
FAS Antibody detects endogenous levels of total FAS.
RRID:
AB_2837827
Cite Format: Affinity Biosciences Cat# AF5342, RRID:AB_2837827.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ALPS 1A; ALPS1A; APO 1; Apo 1 antigen; APO 1 cell surface antigen; Apo-1 antigen; APO1; Apo1 antigen; APO1 cell surface antigen; Apoptosis antigen 1; Apoptosis mediating surface antigen FAS; Apoptosis-mediating surface antigen FAS; APT 1; APT1; CD 95; CD 95 antigen; CD95; CD95 antigen; Delta Fas; Delta Fas/APO 1/CD95; Delta Fas/APO1/CD95; Fas (TNF receptor superfamily, member 6); FAS 1; FAS 827dupA; Fas AMA; Fas; FAS Antigen; Fas cell surface death receptor; FAS1; FASLG receptor; FASTM; sFAS; Surface antigen APO1; TNF receptor superfamily, member 6; TNFRSF 6; TNFRSF6; TNR6_HUMAN; Tumor necrosis factor receptor superfamily member 6;

Immunogens

Immunogen:
Uniprot:

P25445(TNR6_HUMAN) >>Visit HPA database.

Gene(ID):
FAS(355)
Expression:
P25445 TNR6_HUMAN:

Isoform 1 and isoform 6 are expressed at equal levels in resting peripheral blood mononuclear cells. After activation there is an increase in isoform 1 and decrease in the levels of isoform 6.

Description:
Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis.
Sequence:
MLGIWTLLPLVLTSVARLSSKSVNAQVTDINSKGLELRKTVTTVETQNLEGLHHDGQFCHKPCPPGERKARDCTVNGDEPDCVPCQEGKEYTDKAHFSSKCRRCRLCDEGHGLEVEINCTRTQNTKCRCKPNFFCNSTVCEHCDPCTKCEHGIIKECTLTSNTKCKEEGSRSNLGWLCLLLLPIPLIVWVKRKEVQKTCRKHRKENQGSHESPTLNPETVAINLSDVDLSKYITTIAGVMTLSQVKGFVRKNGVNEAKIDEIKNDNVQDTAEQKVQLLRNWHQLHGKKEAYDTLIKDLKKANLCTLAEKIQTIILKDITSDSENSNFRNEIQSLV

PTMs - P25445 As Substrate

Site PTM Type Enzyme
T28 O-Glycosylation
K33 Ubiquitination
T40 O-Glycosylation
T42 O-Glycosylation
T43 O-Glycosylation
T46 O-Glycosylation
Y91 Phosphorylation
N118 N-Glycosylation
K204 Ubiquitination
S209 Phosphorylation
S212 Phosphorylation
T214 Phosphorylation
T219 Phosphorylation
S225 Phosphorylation
S230 Phosphorylation
Y232 Phosphorylation
T234 Phosphorylation
T241 Phosphorylation
S243 Phosphorylation
K263 Ubiquitination
K274 Ubiquitination
K287 Ubiquitination
K288 Ubiquitination
Y291 Phosphorylation
T293 Phosphorylation
K296 Ubiquitination
K300 Ubiquitination
T305 Phosphorylation
K309 Ubiquitination
T312 Phosphorylation
K316 Ubiquitination
S320 Phosphorylation
S322 Phosphorylation
S325 Phosphorylation
S333 Phosphorylation

Research Backgrounds

Function:

Receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. The secreted isoforms 2 to 6 block apoptosis (in vitro).

PTMs:

N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein.

Secreted.

Secreted.

Secreted.

Secreted.

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Isoform 1 and isoform 6 are expressed at equal levels in resting peripheral blood mononuclear cells. After activation there is an increase in isoform 1 and decrease in the levels of isoform 6.

Subunit Structure:

Binds DAXX. Interacts with HIPK3 (By similarity). Part of a complex containing HIPK3 and FADD (By similarity). Binds RIPK1 and FAIM2. Interacts with BABAM2 and FEM1B. Interacts with FADD. Interacts directly (via DED domain) with NOL3 (via CARD domain); inhibits death-inducing signaling complex (DISC) assembly by inhibiting the increase in FAS-FADD binding induced by FAS activation (By similarity). Interacts with CALM. In the absence of stimulation, interacts with BIRC2, DDX3X and GSK3B. The interaction with BIRC2 and DDX3X is further enhanced upon receptor stimulation and accompanied by DDX3X and BIRC2 cleavage.

Family&Domains:

Contains a death domain involved in the binding of FADD, and maybe to other cytosolic adapter proteins.

Research Fields

· Cellular Processes > Cell growth and death > p53 signaling pathway.   (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis.   (View pathway)

· Cellular Processes > Cell growth and death > Necroptosis.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Endocrine and metabolic diseases > Type I diabetes mellitus.

· Human Diseases > Neurodegenerative diseases > Alzheimer's disease.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > African trypanosomiasis.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > Herpes simplex infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Immune diseases > Autoimmune thyroid disease.

· Human Diseases > Immune diseases > Allograft rejection.

· Human Diseases > Immune diseases > Graft-versus-host disease.

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

References

1). Amelioration of nonalcoholic fatty liver disease by swertiamarin in fructose-fed mice. Phytomedicine, 2019 (PubMed: 31005808) [IF=7.9]

Application: IHC    Species: mouse    Sample: liver

Figure.7. |Effect of swertiamarin (25, 50 and 100 mg/kg) and silibinin on (A) ACC1 expression by western blotting analysis. Immunohistochemical stainings of (B) SREBP-1 and (C) FAS in liver tissue of mice. Scale bar represents 30 μm. Representative analysis from six animals in each group.Significance is represented as ##P ≤ 0.01 and ###P ≤ 0.001 compared to the normal control group,*P ≤ 0.05 and **P ≤ 0.01 compared to the fructose group.
2). Effects of Bisphenol A on reproductive toxicity and gut microbiota dysbiosis in male rats. Ecotoxicology and Environmental Safety, 2022 (PubMed: 35567931) [IF=6.8]

Application: WB    Species: Rat    Sample: testes tissue

Fig. 4. Effects of BPA exposure on cell apoptosis in testes. (A) Western blotting photographs and relative quantitative analysis of (B) Cleaved-PARP and PARP protein, (C) FASL, (D) FAS, (E) Cleaved-caspase3, (F) Caspase3, (G) Bcl-2, (H) Bax, and (I) Bcl-2/Bax. Data are expressed as mean ± SD (n = 4). Different letters indicate significant differences between groups (P 
3). 20 (S)-Ginsenoside Rh2 induces caspase-dependent PML-RARA degradation in NB4 cells via Akt/Bax/caspase9 and TNF-α/caspase8 signaling cascades. Journal of Ginseng Research, 2021 (PubMed: 33841010) [IF=6.3]

Application: WB    Species: Human    Sample: NB4 cells

Fig. 7. GRh2 activated the TNF-a/caspase8 cascade. (A) NB4 cells were incubated with 30 mM, 40 mM, or 50 mM GRh2 for 12 h. Protein expression levels of FasL, Fas, TNF-a, and TNFR1 in NB4 cells were detected via Western blot. A representative picture of three replicates is shown. (B) Quantitative statistical graph of the relative protein expression levels. The results are shown as the mean  SD (n ¼ 3) *p < 0.05, **p < 0.01. (C) RT-PCR was used to detect the mRNA expression level of TNF-a in NB4 cells after GRh2 administration. The results are shown as the mean  SD (n ¼ 3) **p < 0.01, ***p < 0.001 versus solvent. After preincubation with 1.5 mM TNF-a inhibitor, C 87, for 2 h, 30 mM, 40 mM, or 50 mM GRh2 was applied for another 12 h. (D) CCK-8 assay measured the NB4 cell viability. The results are shown as the mean  SD (n ¼ 6) ***p < 0.001, ###p < 0.001. (E) Hoechst 33258 staining was used to observe changes in nuclear morphology of NB4 cells after GRh2 and C 87 administration (800  ). (F) Quantitative statistical graph of caspase8 cleavage activation levels in NB4 cells. The Ac-IETD-pNA method was used. The results are shown as the mean  SD (n ¼ 3) ***p < 0.001, #p < 0.05. GRh2, 20(S)-ginsenoside Rh2.
4). Propionate Ameliorates Alcohol-Induced Liver Injury in Mice via the Gut–Liver Axis: Focus on the Improvement of Intestinal Permeability. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2022 (PubMed: 35549256) [IF=6.1]
5). Patchouli alcohol ameliorates acute liver injury via inhibiting oxidative stress and gut-origin LPS leakage in rats. International Immunopharmacology, 2021 (PubMed: 34182243) [IF=5.6]
6). Protective effects of Lactobacillus acidophilus NX2-6 against oleic acid-induced steatosis, mitochondrial dysfunction, endoplasmic reticulum stress and inflammatory responses. Journal of Functional Foods, 2020 [IF=5.6]
7). Tangeretin prevents obesity by modulating systemic inflammation, fat browning, and gut microbiota in high-fat diet-induced obese C57BL/6 mice. JOURNAL OF NUTRITIONAL BIOCHEMISTRY, 2022 (PubMed: 35017003) [IF=5.6]
8). Buyang huanwu decoction alleviates stroke-induced immunosuppression in MCAO mice by reducing splenic T cell apoptosis triggered by AIM2 inflammasome. Journal of ethnopharmacology, 2024 (PubMed: 38906338) [IF=5.4]
9). N-linoleyltyrosine ameliorates high-fat diet-induced obesity in C57BL/6 mice via cannabinoid receptor regulation. Frontiers in Endocrinology, 2022 (PubMed: 36111301) [IF=5.2]

Application: WB    Species: Mouse    Sample:

Figure 6 Effect of NITyr on the expression of key factors in adipogenesis. (A) Western blot analysis of PPAR-γ, FAS and p-AMPK. (B) PPAR-γ expressions were normalized that of GAPDH. (C) FAS expressions were normalized that of GAPDH. (D) p-AMPK expressions were normalized that of AMPK. The control or DIO group was treated with Poloxamer 188 aqueous solution. 30 NITyr, 60 NITyr and 100 NITyr were treated with 30 mg/kg NITyr, 60 mg/kg NITyr, 100 mg/kg NITyr, respectively. All values were expressed as means ± SD. (n = 3). * P < 0.05, ** P < 0.01, *** P < 0.001, as compared with the DIO group.
10). Bisimidazolium Salt Glycosyltransferase Inhibitors Suppress Hepatocellular Carcinoma Progression In Vitro and In Vivo. Pharmaceuticals, 2022 (PubMed: 35745636) [IF=4.6]

Application: WB    Species: Human    Sample: HepG2 cells

Figure 5 C20/C22 increased the sensitivity of HepG2 cells to TRAIL-induced apoptosis. (A,B) WB analysis of the expression of DR4 and 5 in HepG2 cells that were treated with 2 μM C20/C22 for 0, 6, 12, and 24 h. ImageJ software was used to calculate the gray value (n = 3). (C,D) The immunofluorescence assays used to determine the intracellular and cell surface distribution of DR4/5. (E,F) Annexin V/PI double staining was used to detect the apoptotic cells after the indicated treatments (n = 3). (G,H) WB analysis of the expression of Fas in HepG2 cells treated with C20/C22 for 0, 6, 12, and 24 h. (I) The immunofluorescence assays used to determine the intracellular and cell surface distribution of Fas. (J,K) Flow cytometry analysis of the apoptotic cells after the indicated treatments (n = 3). Scale bars, 10 µm. Data shown correspond to the mean ± SD of three independent experiments. The p-value for all datasets was analyzed by one-way ANOVA followed by Tukey’s test using GraphPad Prism version 8.00, except the data in (B) whose p-value was analyzed by nonparametric Dunnett’s test using GraphPad Prism version 8.00. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns nonsignificant vs. 0 h/control group.

Application: IF/ICC    Species: Human    Sample: HepG2 cells

Figure 5 C20/C22 increased the sensitivity of HepG2 cells to TRAIL-induced apoptosis. (A,B) WB analysis of the expression of DR4 and 5 in HepG2 cells that were treated with 2 μM C20/C22 for 0, 6, 12, and 24 h. ImageJ software was used to calculate the gray value (n = 3). (C,D) The immunofluorescence assays used to determine the intracellular and cell surface distribution of DR4/5. (E,F) Annexin V/PI double staining was used to detect the apoptotic cells after the indicated treatments (n = 3). (G,H) WB analysis of the expression of Fas in HepG2 cells treated with C20/C22 for 0, 6, 12, and 24 h. (I) The immunofluorescence assays used to determine the intracellular and cell surface distribution of Fas. (J,K) Flow cytometry analysis of the apoptotic cells after the indicated treatments (n = 3). Scale bars, 10 µm. Data shown correspond to the mean ± SD of three independent experiments. The p-value for all datasets was analyzed by one-way ANOVA followed by Tukey’s test using GraphPad Prism version 8.00, except the data in (B) whose p-value was analyzed by nonparametric Dunnett’s test using GraphPad Prism version 8.00. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, and ns nonsignificant vs. 0 h/control group.
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.